Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027

Zura Bio Ltd

2025-Q3 EPS reported -$0.57

Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.
Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.
Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.
G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.
No revenue reported; clinical-stage immunology company with no approved products.

item 2.02 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001104659-25-110789
form_type: 8-K
ticker: ZURA
cik: 0001855644
company_name: Zura Bio Ltd
filed_at: 2025-11-13T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.836445+00:00
generated_at: 2026-05-16T20:36:06.342009+00:00
sec_items: ["2.02", "9.01"]
event_type: earnings
sentiment: neutral
materiality_score: 0.55
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001104659-25-110789
json_url: https://secwatch.observer/filing/0001104659-25-110789.json
markdown_url: https://secwatch.observer/filing/0001104659-25-110789.md
text_url: https://secwatch.observer/filing/0001104659-25-110789.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/0001104659-25-110789-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/tm2531128d1_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001104659-25-110789

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.